Lupi Matteo, Martinotti Giovanni, Acciavatti Tiziano, Pettorruso Mauro, Brunetti Marcella, Santacroce Rita, Cinosi Eduardo, Di Iorio Giuseppe, Di Nicola Marco, Di Giannantonio Massimo
Department of Neuroscience and Imaging, University "G. d'Annunzio", Chieti, Italy.
Department of Psychiatry, Drug Addiction Unit, Catholic University Medical School, Rome, Italy.
Biomed Res Int. 2014;2014:537306. doi: 10.1155/2014/537306. Epub 2014 May 18.
Gambling disorder (GD) is a psychiatric condition associated with both social and family costs; DSM-5 currently includes GD among addictive disorders. Despite the high burden of this condition, to date there are no treatment guidelines approved by Food and Drug Administration (FDA). Purpose of this paper is to offer a qualitative overview about the different pharmacologic agents used for the treatment of GD. Our analysis, conducted on a final selection of 75 scientific papers, demonstrates that a variety of pharmaceutical classes have been utilised, with different results. Published data, although limited by brief duration of the studies and small number of enrolled subjects, shows mixed evidence for serotonergic antidepressants, opioid antagonists, and mood stabilizers. Other compounds, such as glutamatergic agents and psychostimulants, deserve further studies.
赌博障碍（GD）是一种与社会和家庭成本相关的精神疾病；《精神疾病诊断与统计手册》第五版（DSM-5）目前将GD列入成瘾性疾病之中。尽管这种疾病负担沉重，但迄今为止，美国食品药品监督管理局（FDA）尚未批准相关治疗指南。本文旨在对用于治疗GD的不同药物制剂进行定性概述。我们对最终筛选出的75篇科学论文进行分析，结果表明已使用了多种药物类别，且效果各异。尽管已发表的数据受限于研究持续时间较短和纳入受试者数量较少，但对于血清素能抗抑郁药、阿片类拮抗剂和心境稳定剂的证据不一。其他化合物，如谷氨酸能药物和精神兴奋剂，值得进一步研究。
